Clinical Trial Update: Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the immunogenicity and safety of GlaxoSmithKline's HPV vaccine 580299 in healthy females aged 15-25, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• HPV vaccine 580299 (Cervarix) (human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2010-03-05